Overlap of disorders of gut–brain interaction: a systematic review and meta-analysis

Fairlie, Thomas; Shah, Ayesha; Talley, Nicholas J.; Chey, William D.; Koloski, Natasha A.; Lee, Yeong Yeh; Gwee, Kok‐Ann; Jones, Michael; Holtmann, Gerald

doi:10.1016/s2468-1253(23)00102-4

Cited by 22 publications

(5 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A variety of factors influence placebo-response rates [ 25 ] and subsequent response to therapy. The heterogeneity could be due to the inherent limitations of the studies included in this meta-analysis including study design and setting (e.g., primary vs. secondary or tertiary care) [ 26 ]. The heterogeneity does not limit the validity of the combined effects since all study-specific results revealed the superiority of STW 5-II over placebo.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of STW 5-II for Functional Dyspepsia Treatment: A Patient Data-Based Meta-Analysis

Andresen,

Shah,

Fink

et al. 2024

Digestion

Self Cite

View full text Add to dashboard Cite

Introduction: Functional dyspepsia (FD) is a chronic relapsing gastroduodenal disorder with limited treatment options. Herbal products, like the six-herb combination STW 5-II, can target multiple FD gastrointestinal symptoms. In this meta-analysis, we evaluated the efficacy and safety of STW 5-II for overall FD, and key symptoms, based on Rome IV criteria. Methods: We systematically screened the literature for randomized controlled clinical studies testing STW 5-II in FD. Meta-analysis was performed using data from individual patients with at least one key FD symptom (fullness, early satiety, or epigastric pain) of at least moderate severity at baseline. ANCOVA-based meta-analyses were performed on improvements in the total symptom sum score, and single symptoms, after 4 and 8 weeks. Safety data were analyzed by calculating odds ratios for all adverse events. Results: Four randomized controlled trials, including 613 patients, were identified, and two were eligible for efficacy analysis. STW 5-II significantly improved the FD symptom sum score (mean difference of 1.74 after 4 weeks and 2.07 after 8 weeks) and key FD symptoms of fullness (0.28 and 0.29), early satiety (0.25 and 0.26), and epigastric/upper abdominal pain (0.26 and 0.3). Treatment-related or severe adverse events did not differ between STW 5-II and placebo. Conclusion: The results support that STW 5-II significantly improves FD symptoms after 4 and 8 weeks of treatment with no difference in relation to safety signals compared to placebo. Thus, STW 5-II can be considered an effective and safe treatment option for FD.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of STW 5-II for Functional Dyspepsia Treatment: A Patient Data-Based Meta-Analysis

Andresen,

Shah,

Fink

et al. 2024

Digestion

Self Cite

View full text Add to dashboard Cite

show abstract

“…Overlap of disorders of gut-brain axis is a common occurrence, with the highest prevalence recorded in tertiary care settings (47.3%). These patients report more severe symptoms and associate psychological comorbidities more frequently [41].…”

Section: Psychosocial Factorsmentioning

confidence: 93%

Gut–Brain Axis, Microbiota and Probiotics—Current Knowledge on Their Role in Irritable Bowel Syndrome: A Review

Marginean,

Popescu,

Drocas

et al. 2023

Gastrointestinal Disorders

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a common digestive disorder with a significant impact on both individuals and society in terms of quality of life and healthcare costs. A growing body of research has identified various communication pathways between the microbiota and the brain in relation to motility disorders, with the gut–brain axis being key to the pathogenesis of IBS. Multiple factors contribute to the pathogenetic pathways in IBS, including immune mechanisms, psychosocial factors, increased oxidative stress and pro-inflammatory cytokine release, as well as genetic and hormonal factors. Increased permeability of the normal intestinal barrier allows bacterial products to access the lamina propria, providing a mechanism for perpetuating chronic inflammation and characteristic symptoms. The microbiota influences inflammatory processes in IBS by altering the balance between pro-inflammatory factors and host defence. Probiotics modulate the pathophysiological mechanisms involved in IBS by influencing the composition of the microbiota and improving intestinal motility disorders, visceral hypersensitivity, immune function of the intestinal epithelium, metabolic processes in the intestinal lumen, dysfunction of the microbiota-GBA, and are recognised as effective and safe in IBS therapy. Our study aimed to provide a comprehensive overview of the relationship between the gut–brain axis, microbiota, and IBS, based on current information.

show abstract

“…Exposure to stress can alter the composition of the gut microbiota, a phenomenon termed dysbiosis, leading to increased intestinal permeability, also known as “leaky gut” [ 43 , 44 ]. This can lead to the translocation of bacterial components into the bloodstream, triggering systemic inflammation, which, in turn, can affect brain function and behavior [ 45 , 46 ].…”

Section: Understanding the Gut–brain Axismentioning

confidence: 99%

Microbiome: The Next Frontier in Psychedelic Renaissance

Kargbo

2023

JoX

View full text Add to dashboard Cite

The psychedelic renaissance has reignited interest in the therapeutic potential of psychedelics for mental health and well-being. An emerging area of interest is the potential modulation of psychedelic effects by the gut microbiome—the ecosystem of microorganisms in our digestive tract. This review explores the intersection of the gut microbiome and psychedelic therapy, underlining potential implications for personalized medicine and mental health. We delve into the current understanding of the gut–brain axis, its influence on mood, cognition, and behavior, and how the microbiome may affect the metabolism and bioavailability of psychedelic substances. We also discuss the role of microbiome variations in shaping individual responses to psychedelics, along with potential risks and benefits. Moreover, we consider the prospect of microbiome-targeted interventions as a fresh approach to boost or modulate psychedelic therapy’s effectiveness. By integrating insights from the fields of psychopharmacology, microbiology, and neuroscience, our objective is to advance knowledge about the intricate relationship between the microbiome and psychedelic substances, thereby paving the way for novel strategies to optimize mental health outcomes amid the ongoing psychedelic renaissance.

show abstract

Overlap of disorders of gut–brain interaction: a systematic review and meta-analysis

Cited by 22 publications

References 84 publications

Efficacy and Safety of STW 5-II for Functional Dyspepsia Treatment: A Patient Data-Based Meta-Analysis

Efficacy and Safety of STW 5-II for Functional Dyspepsia Treatment: A Patient Data-Based Meta-Analysis

Gut–Brain Axis, Microbiota and Probiotics—Current Knowledge on Their Role in Irritable Bowel Syndrome: A Review

Microbiome: The Next Frontier in Psychedelic Renaissance

Contact Info

Product

Resources

About